Inflammatory process in Alzheimer's Disease

Frontiers in Integrative Neuroscience

Volumn , Issue JUL, 2013, Pages

  Meraz Ríos, Marco A ^a   Toral Rios, Danira ^a   Franco Bocanegra, Diana ^b   Villeda Hernández, Juana ^c   Campos Peña, Victoria ^c  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Alzheimer disease; Amyloid ; Anti inflammatory strategies; Astrocyte; Microglia; Neurodegeneration; Neuroinflammation; Pro inflammatory cytokine

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CELECOXIB; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; CORTICOSTERONE; CYCLOOXYGENASE 2; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IBUPROFEN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; MEFENAMIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; NAPROXEN; PREDNISONE; ROFECOXIB; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIFLUSAL;

ALZHEIMER DISEASE; ARTHRITIS; ASTROCYTE; COMPLEMENT SYSTEM; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIZZINESS; ENTORHINAL CORTEX; FATIGUE; HIPPOCAMPAL CA1 REGION; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INFLAMMATION; MEDIATOR RELEASE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NONHUMAN; OLIGODENDROGLIA; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; SENILE PLAQUE;

EID: 84882665749     PISSN: 16625145     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnint.2013.00059     Document Type: Review

References (178)

1. Ager, R. R., Fonseca, M. I., Chu, S. H., Sanderson, S. D., Taylor, S. M., Woodruff, T. M., et al. (2010). Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J. Neurochem. 113, 389-401. doi: 10.1111/j.1471-4159.2010.06595.x
2. Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., et al. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588-593. doi: 10.1212/WNL.54.3.588
3. Aisen, P. S., Schaffer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., et al. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer's Disease progression. a randomized controlled trial. JAMA 289, 2819-2826. doi:10.1001/jama.289.21.2819
4. Akama, K. T., Albanese, C., Pestell, R. G., and Van Eldik, L. J. (1998). Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95, 5795-5800. doi: 10.1073/pnas.95.10.5795
5. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., et al. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421. doi: 10.1016/S0197-4580(00)00124-X
6. Akiyama, H., Kondo, H., Mori, H., Kametani, F., Nishimura, T., Ikeda, K., et al. (1996). The aminoterminally truncated forms of amyloid beta-protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients. Neurosci. Lett. 219, 115-118. doi: 10.1016/S0304-3940(96)13197-9
7. Ashutosh, Kou W., Cotter, R., Borgmann, K., Wu, L., Persidsky, R., et al. (2011). CXCL8 protects human neurons from amyloid-beta-induced neurotoxicity: relevance to Alzheimer's disease. Biochem. Biophys. Res. Commun. 412, 565-571. doi: 10.1016/j.bbrc.2011.07.127
8. Austin, S. A., Santhanam, A. V., and Katusic, Z. S. (2010). Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res. 107, 1498-1502. doi: 10.1161/CIRCRESAHA.110.233080
9. Avramovich, J., Amit, T., and Youdim, M. B. H. (2002). Non-steroidal anti-inflammatory drugs stimulate secretion of on-amyloidogenic precursor protein. J. Biol. Chem. 277, 31466-31473. doi: 10.1074/jbc.M201308200
10. Barnes, P. J. (2006). How corticos-teroids control inflammation: quintiles prize lecture 2005. Br. J. Pharmacol. 148, 245-254. doi: 10.1038/sj.bjp.0706736
11. Beato, M., Chalepakis, G., Schauer, M., and Slater, E. P. (1989). DNA regulatory elements for steroid hormones. J. Steroid Biochem. 32, 737-747. doi: 10.1016/0022-4731(89)90521-9
12. Beeri, M. S., Schmeidler, J., Lesser, G. T., Maroukian, M., West, R., Leung, S., et al. (2012). Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol. Aging 33, 1258-1264. doi: 10.1016/j.neurobiolaging.2011.02.011
13. Bendlin, B. B., Newman, L. M., Ries, M. L., Puglielli, L., Carlsson, C. M., Sager, M. A., et al. (2010). NSAIDs may protect against agerelated brain atrophy. Front. Aging Neurosci. 2, 1-8. doi: 10.3389/fnagi.2010.00035
14. Bishop, A., and Anderson, J. E. (2005). NO signaling in the CNS: from the physiological to the pathological. Toxicology 208, 193-205. doi: 10.1016/j.tox.2004.11.034
15. Blasko, I., Stampfer-Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P., and Grubeck-Loebenstein, B. (2004). How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3, 169-176. doi: 10.1111/j.1474-9728.2004.00101.x
16. Blasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, P., and Grubeck-Loebenstein, B. (2000). Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis. 7, 682-689. doi: 10.1006/nbdi.2000.0321
17. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P. (1995). Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20. doi: 10.1016/0304-3940(95)12192-7
18. Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., and Rosenmann, H. (2010). Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472-485. doi: 10.1016/j.expneurol.2010.05.010
19. Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2010). Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559-16566. doi: 10.1523/JNEUROSCI.4363-10.2010
20. Breder, C. D., Dewitt, D., and Kraig, R. P. (1995). Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355, 296-315. doi: 10.1002/cne.903550208
21. Breitner, J. C. S., Haneuse, S. J. P. A., Walker, R., Dublin, S., Crane, P. K., Gray, S. L., et al. (2009). Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905. doi: 10.1212/WNL.0b013e3181a18691
22. Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., et al. (2000). Anti-inflammatory drugs protect against Alzheimer's Disease at low doses. Arch. Neurol. 57, 1586-1591. doi: 10.1001/archneur.57.11.1586
23. Budas, G., Coughlan, C. M., Seckl, J. R., and Breen, K. C. (1999). The effect of corticosteroids on amyloid β precursor protein/amyloid precursor-like protein expression and processing in vivo. Neurosci. Lett. 276, 61-64. doi: 10.1016/S0304-3940(99)00790-9.
24. Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., et al. (2005). Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25, 9096-9101. doi: 10.1523/JNEUROSCI.1697-05.2005
25. Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., and Stella, A. M. (2007). Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. 8, 766-775. doi: 10.1038/nrn2214
26. Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arevalo-Serrano, J., and Gonzalo-Ruiz, A. (2012). Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp. Neurol. 236, 215-227. doi: 10.1016/j.expneurol.2012.05.004
27. Coma, M., Serenó, L., Da Rocha-Souto, B., Scotton, T. C., España, J., Sánchez, M. B., et al. (2010). Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 38, 482-491.
28. Combs, C. K., Karlo, J. C., Kao, S. C., and Landreth, G. E. (2001). beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188.
29. Correa, J. D., Starling, D., Teixeira, A. L., Caramelli, P., and Silva, T. A. (2011). Chemokines in CSF of Alzheimer's disease patients. Arq. Neuropsiquiatr. 69, 455-459. doi: 10.1590/S0004-282X2011000400009
30. Coté, S., Carmichael, P.-H., Verrault, R., Lindsay, J., Lefebvre, J., and Laurin, D. (2012). Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 8, 219-226. doi: 10.1016/j.jalz.2011.03.012
31. Cotman, C., and Anderson, A. (1995). A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10, 19-45. doi: 10.1007/BF02740836
32. Cyster, J. G. (1999). Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102. doi: 10.1126/science.286.5447.2098
33. Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., et al. (2011). Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467. doi: 10.1074/jbc.M111.229633
34. Chakrabarty, P., Jansen-West, K., Beccard, A., Ceballos-Diaz, C., Levites, Y., Verbeeck, C., et al. (2010). Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 24, 548-559. doi: 10.1096/fj.09-141754
35. Chartier-Harlin, M. C., Crawford, F., Hamandi, K., Mullan, M., Goate, A., Hardy, J., et al. (1991). Screening for the beta-amyloid precursor protein mutation (APP717: Val-Ile) in extended pedigrees with early onset Alzheimer's disease. Neurosci. Lett. 129, 134-135. doi: 10.1016/0304-3940(91)90738-F
36. Chibnik, L. B., Shulman, J. M., Leurgans, S. E., Schneider, J. A., Wilson, R. S., Tran, D., et al. (2011). CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann. Neurol. 69, 560-569. doi: 10.1002/ana.22277
37. Choi, S. H., and Bosetti, F. (2009). Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging 1, 234-244.
38. Desai, M. K., Guercio, B. J., Narrow, W. C., and Bowers, W. J. (2011). An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia 59, 627-640. doi: 10.1002/glia.21131
39. Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P., and Yen, S. H. (1988). Alzheimer's disease. a double-labeling immuno-histochemical study of senile plaques. Am. J. Pathol. 132, 86-101.
40. Dickson, D. W., and Rogers, J. (1992). Neuroimmunology of Alzheimer's Disease: a conference report. Neurobiol. Aging 13, 793-798. doi: 10.1016/0197-4580(92)90104-6
41. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B. A., et al. (1998). Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073.
42. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-Tur, J., et al. (1996). Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713. doi: 10.1038/383710a0
43. El Khoury, J., Hickman, S. E., Thomas, C. A., Loike, J. D., and Silverstein, S. C. (1998). Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol. Aging 19, S81-S84. doi: 10.1016/S0197-4580(98)00036-0
44. Fan, R., Defilippis, K., and Van Nostrand, W. E. (2007). Induction of complement proteins in a mouse model for cerebral microvascular a beta deposition. J. Neuroinflammation 4, 22. doi: 10.1186/1742-2094-4-22
45. Fiala, M., Zhang, L., Gan, X., Sherry, B., Taub, D., Graves, M. C., et al. (1998). Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol. Med. 4, 480-489.
46. Fillit, H., Ding, W., Buee, L., Kalman, J., Alstiel, L., Lawlor, B., et al. (1991). Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129, 318-320. doi: 10.1016/0304-3940(91)90490-K
47. Flanders, K. C., Lippa, C. F., Smith, T. W., Pollen, D. A., and Sporn, M. B. (1995). Altered expression of transforming growth factor-beta in Alzheimer's disease. Neurology 45, 1561-1569. doi: 10.1212/WNL.45.8.1561
48. Flower, R. J., Harvey, E. A and Kingston, W. P. (1976). Inflammatory effects of prostaglandin D2 in rat and human skin. Br. J. Pharmacol. 56, 229-233. doi: 10.1111/j.1476-5381.1976.tb07446.x
49. Fonseca, M. I., Ager, R. R., Chu, S. H., Yazan, O., Sanderson, S. D., Laferla, F. M., et al. (2009). Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183, 1375-1383. doi: 10.4049/jimmunol.0901005
50. Fonseca, M. I., Zhou, J., Botto, M., and Tenner, A. J. (2004). Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24, 6457-6465. doi: 10.1523/ JNEUROSCI.0901-04.2004
51. Forneris, F., Wu, J., and Gros, P. (2012). The modular serine proteases of the complement cascade. Curr. Opin. Struct. Biol. 22, 333-341. doi: 10.1016/j.sbi.2012.04.001
52. Fourrier, A., Letenneur, L., Bégaud, B., and Dartigues, J. F. (1996). Nonsteroidal anti-inflammatory drug use and cognitive function in the elderly: inconclusive results from a population.based cohort study. J. Clin. Epidmiol. 49, 1201. doi: 10.1016/0895-4356(96) 00202-8
53. Frackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., and Wang, K. C. (1992). Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 84, 225-233. doi: 10.1007/BF00227813
54. Galimberti, D., Schoonenboom, N., Scarpini, E., and Scheltens, P. (2003). Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann. Neurol. 53, 547-548. doi: 10.1002/ana.10531
55. Gate, D., Rezai-Zadeh, K., Jodry, D., Rentsendorj, A., and Town, T. (2010). Macrophages in Alzheimer's disease: the blood-borne identity. J. Neural Transm. 117, 961-970. doi: 10.1007/s00702-010-0422-7
56. Glenner, G. G., Wong, C. W., Quaranta, V., and Eanes, E. D. (1984). The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl. Pathol. 2, 357-369.
57. Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706. doi: 10.1038/349704a0
58. Goldgaber, D., Harris, H. W., Hla, T., Maciag, T., Donnelly, R. J., Jacobsen, J. S., et al. (1989). Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 86, 7606-7610. doi: 10.1073/pnas.86.19.7606
59. Goodwin, J. L., Kehrli, M. E. Jr., and Uemura, E. (1997). Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. Brain Res. 768, 279-286. doi: 10.1016/S0006-8993(97)00653-7
60. Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., and Laferla, F. M. (2006). Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 26, 9047-9056. doi: 10.1523/JNEUROSCI.2797-06.2006
61. Griffin, W. S., Sheng, J. G., Roberts, G. W., and Mrak, R. E. (1995). Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54, 276-281. doi: 10.1097/00005072-199503000-00014
62. Griffin, W. S., Stanley, L. C., Ling, C., White, L., Macleod, V., Perrot, L. J., et al. (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 86, 7611-7615. doi: 10.1073/pnas.86.19.7611
63. Guix, F. X., Wahle, T., Vennekens, K., Snellinx, A., Chavez-Gutierrez, L., Ill-Raga, G., et al. (2012). Modification of gamma-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. EMBO Mol. Med. 4, 660-673. doi: 10.1002/emmm.201200243
64. Haga, S., Ikeda, K., Sato, M., and Ishii, T. (1993). Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 601, 88-94. doi: 10.1016/0006-8993(93)91698-R
65. Halassa, M. M., and Haydon, P. G. (2010). Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72, 335-355. doi: 10.1146/annurev-physiol-021909-135843
66. Henneberger, C., Papouin, T., Oliet, S. H., and Rusakov, D. A. (2010). Long-term potentiation depends on release of D-serine from astrocytes. Nature 463, 232-236. doi: 10.1038/nature08673
67. Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H.-U., Bulic, B., et al. (2012). No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, 833.e39-833.e50. doi: 10.1016/j.neurobiolaging.2011.08.006
68. Hirohata, M., Ono, K., Naiki, H., and Yamada, M. (2005). Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's ß-amyloid fibrils in vitro. Neuropharmacology 49, 1088-1099. doi: 10.1016/j.neuropharm.2005.07.004
69. Ho, L., Purohit, D., Haroutunian, V., Luterman, J. D., Willis, F., Naslund, J., et al. (2001). Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 58, 487-492. doi: 10.1001/archneur.58.3.487
70. Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., et al. (2003). Antibodies against ß-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554. doi: 10.1016/S0896-6273(03)00294-0
71. Hoozemans, J. J., Van Haastert, E. S., Veerhuis, R., Arendt, T., Scheper, W., Eikelenboom, P., et al. (2005). Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J. Neuroinflammation 2, 27. doi: 10.1186/1742-2094-2-27
72. Hoozemans, J. J., Veerhuis, R., Janssen, I., Rozemuller, A. J., and Eikelenboom, P. (2001). Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Exp. Gerontol. 36, 559-570. doi: 10.1016/S0531-5565(00)00226-6
73. Hull, M., Berger, M., Volk, B., and Bauer, J. (1996). Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann. N.Y. Acad. Sci. 777, 205-212. doi: 10.1111/j.1749-6632.1996. tb34420.x
74. In'T Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L., Van Duijn, C. M., Stijnen, T., et al. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's Disease. N. Eng. J. Med. 345, 1515-1521. doi: 10.1056/NEJMoa010178
75. Ishizuka, K., Kimura, T., Igata-Yi, R., Katsuragi, S., Takamatsu, J., and Miyakawa, T. (1997). Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51, 135-138. doi: 10.1111/j.1440-1819.1997.tb02375.x
76. Iversen, L. L., Mortishire-Smith, R. J., Pollack, S. J., and Shearman, M. S. (1995). The toxicity in vitro of beta-amyloid protein. Biochem. J. 311(Pt 1), 1-16.
77. Jiang, H., Hampel, H., Prvulovic, D., Wallin, A., Blennow, K., Li, R., et al. (2011). Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol. Neurodegener. 6, 69. doi: 10.1186/1750-1326-6-69
78. Jonker, C., Comijs, H. C., and Smit, J. H. (2003). Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol. Aging 24, 583-588. doi: 10.1016/S0197-4580(02)00188-4
79. Joo, Y., Kim, H.-S., Woo, R.-S., Park, C. H., Shin, K.-Y., Lee, J.-P., et al. (2006). Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's Disease models. Mol. Pharmacol. 69, 76-84.
80. Kamata, H., Honda, S., Maeda, S., Chang, L., Hirata, H., and Karin, M. (2005). Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661. doi: 10.1016/j.cell.2004.12.041
81. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736. doi: 10.1038/325733a0
82. Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., et al. (2004). Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 279, 50310-50320. doi: 10.1074/jbc.M405600200
83. Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., et al. (2011). Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol. 187, 6539-6549. doi: 10.4049/jimmunol.1100620
84. Kitazawa, M., Yamasaki, T. R., and Laferla, F. M. (2004). Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. N.Y. Acad. Sci. 1035, 85-103. doi: 10.1196/annals.1332.006
85. Kobayashi, K., Hayashi, M., Nakano, H., Fukutani, Y., Sasaki, K., Shimazaki, M., et al. (2002). Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 28, 238-251. doi: 10.1046/ j.1365-2990.2002.00390.x
86. Konig, H. G., Kogel, D., Rami, A., and Prehn, J. H. (2005). TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling. J. Cell Biol. 168, 1077-1086. doi: 10.1083/jcb.200407027
87. Krieglstein, K., Strelau, J., Schober, A., Sullivan, A., and Unsicker, K. (2002). TGF-beta and the regulation of neuron survival and death. J. Physiol. Paris 96, 25-30. doi: 10.1016/ S0928-4257(01)00077-8
88. Kummer, M. P., Hulsmann, C., Hermes, M., Axt, D., and Heneka, M. T. (2012). Nitric oxide decreases the enzymatic activity of insulin degrading enzyme in APP/PS1 mice. J. Neuroimmune Pharmacol. 7, 165-172. doi: 10.1007/s11481-011-9339-7
89. Laske, C., Stransky, E., Fritsche, A., Eschweiler, G., and Leyhe, T. (2009). Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Aβ 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia. Eur. Arch. Psychiatry Clin. Neurosci. 259, 80-85. doi: 10.1007/s00406-008-0838-3
90. Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A., Weber, J. L., et al. (1995). A familial Alzheimer's disease locus on chromosome 1. Science 269, 970-973. doi: 10.1126/science.7638621
91. Li, G., Shen, Y. C., Li, Y. T., Chen, C. H., Zhau, Y. W., and Silverman, J. M. (1992). A case-control study of Alzheimer's disease in China. Neurology 42, 1481-1488. doi: 10.1212/WNL.42.8.1481
92. Li, W.-Z., Li, W.-P., Yao, Y.-Y., Zhang, W., Yin, Y.-Y., Wu, G.-C., et al. (2010). Glucocorticoids increase impairments in learning and memory due to elevated amyloid precursor protein expression and neuronal apoptosis in 12-month old mice. Eur. J. Pharmacol. 628, 108-115. doi: 10.1016/j.ejphar.2009.11.045
93. Li, Y., Liu, L., Barger, S. W., and Griffin, W. S. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23, 1605-1611.
94. Li, Y., Wang, J., Sheng, J. G., Liu, L., Barger, S. W., Jones, R. A., et al. (1998). S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J. Neurochem. 71, 1421-1428. doi: 10.1046/j.1471-4159.1998.71041421.x
95. Liao, Y. F., Wang, B. J., Cheng, H. T., Kuo, L. H., and Wolfe, M. S. (2004). Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretasemediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 279, 49523-49532. doi: 10.1074/jbc.M402034200
96. Liu, B., Gao, H. M., Wang, J. Y., Jeohn, G. H., Cooper, C. L., and Hong, J. S. (2002). Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N.Y. Acad. Sci. 962, 318-331. doi: 10.1111/j.1749-6632.2002.tb04077.x
97. Liu, Y., Lee, M. K., James, M. M., Price, D. L., Borchelt, D. R., Troncoso, J. C., et al. (2011). Passive (Amyloid-β Immunotherapy Attenuates Monoaminergic Axonal Degeneration in the AβPPswe/PS1dE9 Mice. J. Alzheimer's Dis. 23, 271-279.
98. Lue, L. F., Rydel, R., Brigham, E. F., Yang, L. B., Hampel, H., Murphy, G. M. Jr., et al., (2001). Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35, 72-79. doi: 10.1002/glia.1072
99. Macpherson, A., Dinkel, K., and Sapolsky, R. (2005). Glucocorticoids worsen excitotoxin-induced expression of pro-inflammatory cytokines in hippocampal cultures. Exp. Neurol. 194, 376-383. doi: 10.1016/j.expneurol.2005.02.021
100. Maier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., and Lemere, C. A. (2008). Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28, 6333-6341. doi: 10.1523/JNEUROSCI.0829-08.2008
101. Man, S. M., Ma, Y. R., Shang, D. S., Zhao, W. D., Li, B., Guo, D. W., et al. (2007). Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Aging 28, 485-496. doi: 10.1016/j.neurobiolaging.2006.02.013
102. Martin, B., Szekely, C., Brandt, J., Piantadosi, S., Breitner, J., Craft, S., et al. (2008). Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896. doi: 10.1001/arch-neur.2008.65.7.nct70006
103. Matousek, S. B., Ghosh, S., Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., and O'Banion, M. K. (2012). Chronic IL-1beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J. Neuroimmune Pharmacol. 7, 156-164. doi: 10.1007/s11481-011-9331-2
104. McAlpine, F. E., Lee, J. K., Harms, A. S., Ruhn, K. A., Blurton-Jones, M., Hong, J., et al. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34, 163-177. doi: 10.1016/j.nbd.2009.01.006
105. McGeer, P. L., Akiyama, H., Itagaki, S., and McGeer, E. G. (1989). Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107, 341-346. doi: 10.1016/0304-3940(89)90843-4
106. McGeer, P. L., Itagaki, S., and McGeer, E. G. (1988). Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76, 550-557. doi: 10.1007/BF00689592
107. McGeer, P. L., and McGeer, E. G. (1995). The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21, 195-218. doi: 10.1016/0165-0173(95)00011-9
108. Meda, L., Baron, P., Prat, E., Scarpini, E., Scarlato, G., Cassatella, M. A., et al. (1999). Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J. Neuroimmunol. 93, 45-52. doi: 10.1016/S0165-5728(98)00188-X
109. Medeiros, R., and Laferla, F. M. (2013). Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp. Neurol. 239, 133-138. doi: 10.1016/j.expneurol.2012.10.007
110. Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., et al. (2011). Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-alpha suppressive therapeutic strategies in the brain. Am. J. Pathol. 179, 2053-2070. doi: 10.1016/j.ajpath.2011.07.001
111. Moynagh, P. N. (2005). The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J. Anat. 207, 265-269. doi: 10.1111/j.1469-7580.2005.00445.x
112. Mrak, R. E. (2012). Microglia in Alzheimer brain: a neuropathological perspective. Int. J. Alzheimers Dis. 2012, 165021. doi: 10.1155/2012/165021
113. Mrak, R. E., and Griffin, W. S. (2005). Potential inflammatory biomarkers in Alzheimer's disease. J. Alzheimers Dis. 8, 369-375.
114. Mrak, R. E., Sheng, J. G., and Griffin, W. S. (1996). Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 273-279. doi: 10.1097/00005072-199603000-00002
115. Murrell, J., Farlow, M., Ghetti, B., and Benson, M. D. (1991). A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254, 97-99. doi: 10.1126/science.1925564
116. Okun, E., Mattson, M. P., and Arumugam, T. V. (2010). Involvement of Fc receptors in disorders of the central nervous system. Neuromol. Med. 12, 164-178. doi: 10.1007/s12017-009-8099-5
117. Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L., et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54. doi: 10.1212/01.WNL.0000073623.84147.A8
118. Patel, N. S., Paris, D., Mathura, V., Quadros, A. N., Crawford, F. C., and Mullan, M. J. (2005). Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J. Neuroinflammation 2, 9. doi: 10.1186/1742-2094-2-9
119. Pekkarinen, P. T., Vaali, K., Junnikkala, S., Rossi, L. H., Tuovinen, H., Meri, S., et al. (2011). A functional complement system is required for normal T helper cell differentiation. Immunobiology 216, 737-743. doi: 10.1016/j.imbio.2010.10.004
120. Quintanilla, R. A., Orellana, D. I., Gonzalez-Billault, C., and Maccioni, R. B. (2004). Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 295, 245-257. doi: 10.1016/j.yexcr.2004.01.002
121. Ransohoff, R. M., Glabinski, A., and Tani, M. (1996). Chemokines in immune-mediated inflammation of the central nervous system. Cytokine Growth Factor Rev. 7, 35-46. doi: 10.1016/1359-6101(96)00003-2
122. Rezai-Zadeh, K., Gate, D., and Town, T. (2009). CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J. Neuroimmune Pharmacol. 4, 462-475. doi: 10.1007/s11481-009-9166-2
123. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010). Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797. doi: 10.1038/ni.1923
124. Ridnour, L. A., Barasch, K. M., Windhausen, A. N., Dorsey, T. H., Lizardo, M. M., Yfantis, H. G., et al. (2012). Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS ONE 7:e44081. doi: 10.1371/journal.pone.0044081
125. Ringman, J. M., O'Neill, J., Geschwind, D., Medina, L., Apostolova, L. G., Rodriguez, Y., et al. (2007). Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 130, 1767-1776. doi: 10.1093/brain/awm102
126. Ringheim, G. E., Szczepanik, A. M., Petko, W., Burgher, K. L., Zhu, S. Z., and Chao, C. C. (1998). Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res. Mol. Brain Res. 55, 35-44. doi: 10.1016/S0169-328X(97)00356-2
127. Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., et al. (1992). Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89, 10016-10020. doi: 10.1073/pnas.89.21.10016
128. Rossi, F., and Bianchini, E. (1996). Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem. Biophys. Res. Commun. 225, 474-478. doi: 10.1006/bbrc.1996.1197
129. Roth, A. D., Ramirez, G., Alarcon, R., and Von Bernhardi, R. (2005). Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol. Res. 38, 381-387. doi: 10.4067/S0716-97602005000400011
130. Rozemuller, J. M., Eikelenboom, P., and Stam, F. C. (1986). Role of microglia in plaque formation in senile dementia of the Alzheimer type. An immunohistochemical study. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 51, 247-254. doi: 10.1007/BF02899034
131. Rozkalne, A., Spires-Jones, T. L., Stern, E. A., and Hyman, B. T. (2009). A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res. 1280, 178-185. doi: 10.1016/j.brainres.2009.05.045
132. Rubartelli, A., and Lotze, M. T. (2007). Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28, 429-436. doi: 10.1016/j.it.2007.08.004
133. Saez, T. E., Pehar, M., Vargas, M., Barbeito, L., and Maccioni, R. B. (2004). Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18, 275-280.
134. Salloway, S., Sperling, R., Gilman, S., Fox, N., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070. doi: 10.1212/WNL.0b013e3181c67808
135. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., et al. (2006). Nonsteroidal anti-inflammatory drugs repress -secretase gene promoter activity by the activation of PPAR. Proc. Natl. Acad. Sci. U.S.A. 103, 443-448.
136. Sheng, J. G., Zhu, S. G., Jones, R. A., Griffin, W. S., and Mrak, R. E. (2000). Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 163, 388-391. doi: 10.1006/exnr.2000.7393
137. Sisodia, S. S., Kim, S. H., and Thinakaran, G. (1999). Function and dysfunction of the presenilins. Am. J. Hum. Genet. 65, 7-12. doi: 10.1086/302475
138. Smyth, M. D., Cribbs, D. H., Tenner, A. J., Shankle, W. R., Dick, M., Kesslak, J. P., et al. (1994). Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol. Aging 15, 609-614. doi: 10.1016/0197-4580(94)00055-7
139. Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35. doi: 10.1007/s00401-009-0619-8
140. Spires-Jones, T. L., Mielke, M. L., Rozkalne, A., Meyer-Luehmann, M., De Calignon, A., Bacskai, B. J., et al. (2009). Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol. Dis. 33, 213-220. doi: 10.1016/j.nbd. 2008.10.011
141. Sterka, D. Jr., and Marriott, I. (2006). Characterization of nucleotide-binding oligomerization domain (NOD) protein expression in primary murine microglia. J. Neuroimmunol. 179, 65-75. doi: 10.1016/j.jneuroim.2006.06.009
142. Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D., et al. (2004). Modulation of nuclear factor-κb activity by indomethacin influences aβ levels but not aβ precursor protein metabolism in a model of alzheimer's disease. Am. J. Pathol. 165, 2197-2206. doi: 10.1016/ S0002-9440(10)63269-5
143. Swaab, D. F., Raadsheer, F. C., Endert, E., Hofman, M. A., Kamphorst, W., and Ravid, R. (1994). Increased cortisol levels in aging and Alzheimer's disease in postmortem cerebrospinal fluid. J. Neuroendocrinol. 6, 681-687. doi: 10.1111/j.1365-2826.1994.tb00635.x
144. Szekely, C. A., Green, R. C., Breitner, J. C. S., Ostbye, T., Beiser, A. S., Corrada, M. M., et al. (2008). No advantage of "Aβ42-lowering" NSAIDs for prevention of AD insix pooled cohort studies. Neurology 70, 2291-2298. doi: 10.1212/01.wnl.0000313933.17796.f6
145. Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., et al. (2006). Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 281, 21362-21368. doi: 10.1074/jbc.M600504200
146. Tan, J., Town, T., Paris, D., Mori, T., Suo, Z., Crawford, F., et al. (1999). Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286, 2352-2355. doi: 10.1126/science.286.5448.2352
147. Tarkowski, E., Issa, R., Sjogren, M., Wallin, A., Blennow, K., Tarkowski, A., et al. (2002). Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23, 237-243. doi: 10.1016/S0197-4580(01)00285-8.
148. Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J.V., et al. (2006). Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 116, 3060-3069. doi: 10.1172/JCI27341
149. Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., et al. (2005). A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30, 1204-1215. doi: 10.1038/sj.npp. 1300690
150. Torreilles, F., Salman-Tabcheh, S., Guerin, M., and Torreilles, J. (1999). Neurodegenerative disorders: the role of peroxynitrite. Brain Res. Brain Res. Rev. 30, 153-163. doi: 10.1016/S0165-0173(99)00014-4
151. Town, T., Nikolic, V., and Tan, J. (2005). The microglial activation continuum: from innate to adaptive responses. J. Neuroinflammation 2, 24. doi: 10.1186/1742-2094-2-24
152. Van Dam, D., Coen, K., and De Deyn, P. P. (2010). Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. J. Psychopharmacol. 24, 383-388. doi: 10.1177/0269881108097630
153. Vane, J., and Botting, R. (1987). Inflammation and the mechanism of action of anti-inflammmatory drugs. FASEB J. 1, 89-96.
154. Vellas, B., Black, R., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., et al. (2009). Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144. doi: 10.2174/156720509787602852
155. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003). Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65. doi: 10.1038/sj.cdd.4401189
156. Walker, D. G., Kim, S. U., and McGeer, P. L. (1995). Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J. Neurosci. Res. 40, 478-493. doi: 10.1002/jnr.490400407
157. Walker, D. G., and Lue, L. F. (2005). Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J. Neurosci. Res. 81, 412-425. doi: 10.1002/jnr.20484
158. Wallace, M. N., Geddes, J. G., Farquhar, D. A., and Masson, M. R. (1997). Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Exp. Neurol. 144, 266-272. doi: 10.1006/exnr.1996.6373
159. Webster, S. D., Yang, A. J., Margol, L., Garzon-Rodriguez, W., Glabe, C. G., and Tenner, A. J. (2000). Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161, 127-138. doi: 10.1006/exnr.1999.7260
160. Wells, T. N., Power, C. A., and Proudfoot, A. E. (1998). Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol. Sci. 19, 376-380. doi: 10.1016/S0165-6147(98)01247-4
161. Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., and Hansson, O. (2012). CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS ONE 7:e30525. doi: 10.1371/journal.pone.0030525
162. Wiessner, C., Wiederhold, K. H., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., et al. (2011). The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 31, 9323-9331. doi: 10.1523/ JNEUROSCI.0293-11.2011
163. Williams, T. J. (1978). The role of prostaglandins in inflammation. Ann. R. Coll. Surg. Engl. 60, 198-201.
164. Wisniewski, H. M., Barcikowska, M., and Kida, E. (1991). Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol. 81, 588-590. doi: 10.1007/BF00310142
165. Wyss-Coray, T., Lin, C., Yan, F., Yu, G. Q., Rohde, M., McConlogue, L., et al. (2001). TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 612-618. doi: 10.1038/87945
166. Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., et al. (2003). Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9, 453-457. doi: 10.1038/nm838
167. Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood, K., Lin, C., et al. (1997). Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389, 603-606. doi: 10.1038/39321
168. Wyss-Coray, T., Yan, F., Lin, A. H., Lambris, J. D., Alexander, J. J., Quigg, R. J., et al. (2002). Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99, 10837-10842. doi: 10.1073/pnas.162350199
169. Xia, M. Q., Qin, S. X., Wu, L. J., Mackay, C. R., and Hyman, B. T. (1998). Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am. J. Pathol. 153, 31-37. doi: 10.1016/S0002-9440(10)65542-3
170. Xiang, Z., Ho, L., Valdellon, J., Borchelt, D., Kelley, K., Spielman, L., et al. (2002a). Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging 23, 327-334. doi: 10.1016/S0197-4580(01)00282-2
171. Xiang, Z., Ho, L., Yemul, S., Zhao, Z., Qing, W., Pompl, P., et al. (2002b). Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 10, 271-278.
172. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., and Worley, P. F. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386. doi: 10.1016/0896-6273(93)90192-T
173. Yamamoto, M., Horiba, M., Buescher, J. L., Huang, D., Gendelman, H. E., Ransohoff, R. M., et al. (2005). Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol. 166, 1475-1485. doi: 10.1016/S0002-9440(10)62364-4
174. Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., et al. (2007). Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 170, 680-692. doi: 10.2353/ajpath.2007.060378
175. Yao, Y.-Y., Liu, D.-M., Xu, D.-F., and Li, W.-P. (2007). Memory and learning impairment induced by dexamethasone in senescent but not young mice. Eur. J. Pharmacol. 574, 20-28. doi: 10.1016/j.ejphar.2007.07.021
176. Yermakova, A. V., Rollins, J., Callahan, L. M., Rogers, J., and O'Banion, M. K. (1999). Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58, 1135-1146. doi: 10.1097/00005072-199911000-00003
177. Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., and Farrer, L. A. (2005). Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 5:2. doi: 10.1186/1471-2318-5-2
178. Zilka, N., Kazmerova, Z., Jadhav, S., Neradil, P., Madari, A., Obetkova, D., et al. (2012). Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflammation 9, 47. doi: 10.1186/1742-2094-9-47